Hisamitsu Pharmaceutical Co Inc
TSE:4530
Hisamitsu Pharmaceutical Co Inc
Long-Term Debt
Hisamitsu Pharmaceutical Co Inc
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Hisamitsu Pharmaceutical Co Inc
TSE:4530
|
Long-Term Debt
¥2.4B
|
CAGR 3-Years
30%
|
CAGR 5-Years
37%
|
CAGR 10-Years
12%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Long-Term Debt
¥4.7T
|
CAGR 3-Years
4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
19%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Long-Term Debt
¥100.9B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-7%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Long-Term Debt
¥160.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
22%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Long-Term Debt
¥4.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
38%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Long-Term Debt
¥564.9B
|
CAGR 3-Years
117%
|
CAGR 5-Years
34%
|
CAGR 10-Years
97%
|
|
Hisamitsu Pharmaceutical Co Inc
Glance View
In the bustling landscape of Japanese pharmaceutical companies, Hisamitsu Pharmaceutical Co., Inc. stands out with its pioneering spirit and deep-rooted dedication to health and wellness. Founded in 1847, the company has evolved over a century and a half, transitioning from a modest establishment selling herbal medicines to a globally recognized manufacturer of pain-relief products. At the core of Hisamitsu's operations is its flagship product, the transdermal patch, featuring the SALONPAS brand as its crown jewel. This innovative delivery system allows active medicinal ingredients to penetrate the skin, addressing pain at its source effectively and efficiently. As global demand for non-invasive pain relief grows, Hisamitsu leverages its expertise in transdermal technology, continuously innovating and expanding its product line to cater to diverse consumer needs. Hisamitsu's success hinges on a solid blend of cutting-edge research, consistent quality, and strategic marketing prowess. By investing heavily in R&D, the company not only enhances its existing product offerings but also explores new therapeutic areas, ensuring a pipeline poised for future growth. Besides Japan, Hisamitsu's market presence extends across the Americas, Europe, and Asia, with international sales contributing significantly to its revenue stream. The company is adept at navigating intricate regulatory landscapes and varying consumer preferences to establish its footprint globally. This strategic expansion, coupled with a relentless commitment to quality, enables Hisamitsu to sustain its profitability while fulfilling its mission of delivering comfort and improved quality of life to people around the world.
See Also
What is Hisamitsu Pharmaceutical Co Inc's Long-Term Debt?
Long-Term Debt
2.4B
JPY
Based on the financial report for Feb 28, 2025, Hisamitsu Pharmaceutical Co Inc's Long-Term Debt amounts to 2.4B JPY.
What is Hisamitsu Pharmaceutical Co Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
12%
Over the last year, the Long-Term Debt growth was 251%. The average annual Long-Term Debt growth rates for Hisamitsu Pharmaceutical Co Inc have been 30% over the past three years , 37% over the past five years , and 12% over the past ten years .
You don't have any saved screeners yet